[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6602152A2 - En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga. - Google Patents

En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga.

Info

Publication number
CO6602152A2
CO6602152A2 CO12125933A CO12125933A CO6602152A2 CO 6602152 A2 CO6602152 A2 CO 6602152A2 CO 12125933 A CO12125933 A CO 12125933A CO 12125933 A CO12125933 A CO 12125933A CO 6602152 A2 CO6602152 A2 CO 6602152A2
Authority
CO
Colombia
Prior art keywords
pays
chapter
payment
presents
request
Prior art date
Application number
CO12125933A
Other languages
English (en)
Inventor
Mark Richard Underwood
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6602152(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of CO6602152A2 publication Critical patent/CO6602152A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a combinaciones de los compuestos que comprenden inhibidores de la integrasa de VIH y otros agentes terapéuticos. Estas combinaciones son útiles en la inhibición de la réplica del VIH, la prevención y/o el tratamiento de la infección por VIH. y en el tratamiento de SIDA y/o ARC.
CO12125933A 2010-01-27 2012-07-26 En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga. CO6602152A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CO6602152A2 true CO6602152A2 (es) 2013-01-18

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12125933A CO6602152A2 (es) 2010-01-27 2012-07-26 En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga.

Country Status (45)

Country Link
US (13) US20120295898A1 (es)
EP (6) EP3127542B1 (es)
JP (8) JP2013518107A (es)
KR (4) KR101964923B1 (es)
CN (2) CN102791129B (es)
AP (1) AP3551A (es)
AU (1) AU2011209788C1 (es)
BR (1) BR112012018670A2 (es)
CA (4) CA3003988C (es)
CL (1) CL2012002080A1 (es)
CO (1) CO6602152A2 (es)
CR (1) CR20120423A (es)
CY (4) CY1116509T1 (es)
DK (4) DK3494972T3 (es)
DO (2) DOP2012000205A (es)
EA (4) EA025176B1 (es)
EC (1) ECSP12012106A (es)
ES (4) ES2670811T3 (es)
FI (2) FI3494972T3 (es)
FR (2) FR18C1043I2 (es)
HK (3) HK1209629A1 (es)
HR (4) HRP20240168T1 (es)
HU (6) HUE026849T2 (es)
IL (5) IL221007A (es)
LT (4) LT3494972T (es)
LU (1) LUC00090I2 (es)
MA (1) MA34002B1 (es)
ME (2) ME03058B (es)
MX (4) MX367938B (es)
MY (2) MY202778A (es)
NO (2) NO2932970T3 (es)
NZ (4) NZ627827A (es)
PE (2) PE20121524A1 (es)
PH (3) PH12012501537A1 (es)
PL (4) PL3127542T3 (es)
PT (4) PT3127542T (es)
RS (4) RS57323B1 (es)
SG (3) SG10201707183TA (es)
SI (4) SI3494972T1 (es)
SM (4) SMT202400063T1 (es)
TN (1) TN2012000376A1 (es)
TR (1) TR201807704T4 (es)
UA (1) UA105556C2 (es)
WO (1) WO2011094150A1 (es)
ZA (1) ZA201205586B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
MX364901B (es) 2012-10-23 2019-05-10 Cipla Ltd Composicion farmaceutica antirretroviral.
HUE028284T2 (en) 2012-12-21 2016-12-28 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
CA2897137A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (es) 2013-07-12 2018-07-21
US9861620B2 (en) 2013-09-27 2018-01-09 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
IN2014MU00916A (es) 2014-03-20 2015-09-25 Cipla Ltd
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
US10189860B2 (en) 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3736274A1 (en) 2015-04-02 2020-11-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3655106A4 (en) * 2017-07-18 2021-04-21 VIIV Healthcare Company COMBINED INGREDIENTS THERAPY
MX2020000790A (es) 2017-07-21 2020-11-11 Viiv Healthcare Co Pautas para el tratamiento de infecciones por el vih y sida.
WO2019016760A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES AND PREPARATIONS FOR THE TREATMENT OF HIV INFECTIONS AND AIDS
CN117281788A (zh) * 2017-10-13 2023-12-26 Viiv保健公司 双层药物片剂制剂
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
WO2021142150A1 (en) * 2020-01-09 2021-07-15 University Of Washington Long-acting therapeutic agent combinations and methods thereof
CN115151545A (zh) 2020-02-24 2022-10-04 吉利德科学公司 用于治疗hiv感染的四环化合物
PE20242099A1 (es) 2021-01-19 2024-10-28 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
EP0938321B1 (en) * 1996-06-25 2004-01-14 Glaxo Group Limited Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (en) 1998-03-27 2001-01-03 The Regents of the University of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
PL211860B1 (pl) 2000-01-31 2012-07-31 Cook Biotech Inc Zespół zastawki stentu
ATE358669T1 (de) 2001-04-10 2007-04-15 Pfizer Pyrazolderivate zur behandlung von hiv
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
WO2004002433A1 (en) * 2002-06-27 2004-01-08 Medivir Ab Synergistic interaction of abacavir and alovudine
BRPI0406760A (pt) * 2003-01-14 2005-12-20 Gilead Sciences Inc Composições e métodos para terapia antiviral de combinação
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
BRPI0507628A (pt) 2004-02-11 2007-07-03 Smithkline Beecham Corp composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
DE602005010413D1 (de) * 2004-04-14 2008-11-27 Zhenhong R Cai Phosphonatanaloga von hiv-integrasehemmerverbindungen
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
SI1799696T1 (sl) 2004-09-17 2009-04-30 Idenix Pharmaceuticals Inc Fosfoindoli kot hiv inhibitorji
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
SI3187225T1 (sl) * 2005-04-28 2022-04-29 Viiv Healthcare Company Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
US20080280849A1 (en) 2005-06-01 2008-11-13 Herve Leh Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
JP4676536B2 (ja) * 2005-12-30 2011-04-27 ギリアド サイエンシズ, インコーポレイテッド Hivインテグラーゼ阻害剤の薬物動態の改善方法
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
USRE50189E1 (en) * 2006-01-20 2024-10-29 Janssen Sciences Ireland Unlimited Company Long term treatment of HIV-infection with TMC278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
NZ573887A (en) 2006-07-21 2012-02-24 Gilead Sciences Inc Antiviral protease inhibitors
EA016267B1 (ru) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
WO2009005693A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
AU2008271114A1 (en) 2007-06-29 2009-01-08 Korea Research Institute Of Chemical Technology Novel HIV reverse transcriptase inhibitors
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
DK2175857T3 (da) * 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CN101977924A (zh) 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
CN101981047A (zh) * 2008-01-03 2011-02-23 Viro化学制药公司 新的羽扇烷衍生物
JP5629585B2 (ja) 2008-01-04 2014-11-19 ギリアード サイエンシーズ, インコーポレイテッド シトクロムp450のインヒビター
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
US8217034B2 (en) * 2008-07-25 2012-07-10 Shionogi & Co., Ltd. Chemical compounds
BRPI0923217A2 (pt) * 2008-12-11 2017-05-23 Glaxosmithkline Llc processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
PT3617194T (pt) * 2008-12-11 2023-11-27 Shionogi & Co Processos e intermediários para inibidores carbamoilpiridona da integrase do vih
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
RU2623039C2 (ru) 2011-04-01 2017-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта

Also Published As

Publication number Publication date
CR20120423A (es) 2012-11-22
EP2932970B1 (en) 2018-03-21
LT2932970T (lt) 2018-06-25
SMT201800290T1 (it) 2018-07-17
EA032868B1 (ru) 2019-07-31
LTC2932970I2 (lt) 2022-04-25
HK1250335A1 (zh) 2018-12-14
RS54123B1 (en) 2015-12-31
AP2012006445A0 (en) 2012-08-31
KR101830715B1 (ko) 2018-04-04
EP3127542A1 (en) 2017-02-08
EA201892277A1 (ru) 2019-03-29
ES2670811T3 (es) 2018-06-01
NO2932970T3 (es) 2018-08-18
EA201690872A3 (ru) 2016-12-30
CY1121040T1 (el) 2019-12-11
PH12016500195B1 (en) 2021-08-04
ES2543066T3 (es) 2015-08-14
KR20160111536A (ko) 2016-09-26
PH12012501537A1 (en) 2018-02-07
RS65183B1 (sr) 2024-03-29
US20120295898A1 (en) 2012-11-22
NO2018036I1 (no) 2018-10-15
PE20121524A1 (es) 2012-12-03
CY2018029I1 (el) 2019-07-10
CA3003988A1 (en) 2011-08-04
US20170216284A1 (en) 2017-08-03
EA202190473A3 (ru) 2021-12-31
HUE037812T2 (hu) 2018-09-28
EP2531027B1 (en) 2015-05-06
EP3351249A1 (en) 2018-07-25
IL281959A (en) 2021-05-31
IL267658A (en) 2019-08-29
CA2787691C (en) 2018-07-17
US20210401850A1 (en) 2021-12-30
BR112012018670A2 (pt) 2018-02-06
HUE026849T2 (en) 2016-08-29
KR20120128640A (ko) 2012-11-27
FI3494972T3 (fi) 2024-03-01
DOP2021000147A (es) 2022-01-16
CA2967453A1 (en) 2011-08-04
US20150238496A1 (en) 2015-08-27
CA3060290A1 (en) 2011-08-04
HUE065569T2 (hu) 2024-06-28
EP3494972A1 (en) 2019-06-12
EP2531027A1 (en) 2012-12-12
SMT201500177B (it) 2015-09-07
LUC00090I2 (es) 2019-01-08
LTPA2018013I1 (lt) 2018-11-12
IL245182A0 (en) 2016-06-30
AP3551A (en) 2016-01-18
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
PL2531027T3 (pl) 2016-01-29
ECSP12012106A (es) 2013-05-31
MY188334A (en) 2021-11-30
US10426780B2 (en) 2019-10-01
FIC20240016I1 (fi) 2024-05-31
JP2022071126A (ja) 2022-05-13
WO2011094150A1 (en) 2011-08-04
DK2932970T3 (en) 2018-05-28
NZ601319A (en) 2014-08-29
CN105311033A (zh) 2016-02-10
JP2019167371A (ja) 2019-10-03
DK2531027T3 (en) 2015-07-20
SMT201800594T1 (it) 2019-01-11
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
EP4316599A2 (en) 2024-02-07
PL3494972T3 (pl) 2024-05-27
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
JP2016145204A (ja) 2016-08-12
CN102791129A (zh) 2012-11-21
ES2969969T3 (es) 2024-05-23
MY202778A (en) 2024-05-21
JP2021091705A (ja) 2021-06-17
HRP20180855T1 (hr) 2018-06-29
MA34002B1 (fr) 2013-02-01
SG10201509476RA (en) 2015-12-30
HRP20150770T1 (hr) 2015-08-28
CA3003988C (en) 2020-01-07
HK1209629A1 (en) 2016-04-08
FR18C1043I1 (es) 2018-11-30
JP2013518107A (ja) 2013-05-20
JP2017008087A (ja) 2017-01-12
ME02182B (me) 2015-10-20
TR201807704T4 (tr) 2018-06-21
IL245182B (en) 2018-04-30
CN105311033B (zh) 2019-05-07
EA037601B1 (ru) 2021-04-20
EA025176B1 (ru) 2016-11-30
US20160339033A1 (en) 2016-11-24
KR20180078358A (ko) 2018-07-09
SMT202400063T1 (it) 2024-03-13
JP2023085431A (ja) 2023-06-20
US20200230147A1 (en) 2020-07-23
EP4316599A3 (en) 2024-04-10
HUE040554T2 (hu) 2019-03-28
SG10201707183TA (en) 2017-10-30
PT3127542T (pt) 2018-11-26
KR101964923B1 (ko) 2019-04-02
US20170281636A1 (en) 2017-10-05
HUS1800042I1 (hu) 2018-11-28
US20170119777A1 (en) 2017-05-04
HUS2400017I1 (hu) 2024-06-28
KR20170078868A (ko) 2017-07-07
EP2932970A1 (en) 2015-10-21
PT2531027E (pt) 2015-09-16
SI2531027T1 (sl) 2015-08-31
IL267658B (en) 2021-04-29
PL2932970T3 (pl) 2018-08-31
MX367938B (es) 2019-09-12
UA105556C2 (uk) 2014-05-26
IL257267A (en) 2018-03-29
NZ627827A (en) 2016-02-26
US20180200254A1 (en) 2018-07-19
PT2932970T (pt) 2018-06-08
CA2967453C (en) 2018-07-17
LT3494972T (lt) 2024-03-12
IL281959B (en) 2021-12-01
JP6268386B2 (ja) 2018-01-31
ES2688925T3 (es) 2018-11-07
HRP20181531T1 (hr) 2018-11-16
PT3494972T (pt) 2024-02-12
AU2011209788A1 (en) 2012-08-16
US20250017939A1 (en) 2025-01-16
EP3127542B1 (en) 2018-08-22
EA201690872A2 (ru) 2016-08-31
AU2011209788C1 (en) 2014-08-28
SI3127542T1 (sl) 2018-11-30
CN102791129B (zh) 2015-09-30
US20160199379A1 (en) 2016-07-14
AU2011209788B2 (en) 2014-02-06
KR101883750B1 (ko) 2018-07-31
US20170079982A1 (en) 2017-03-23
CL2012002080A1 (es) 2012-11-30
JP2018127473A (ja) 2018-08-16
ME03058B (me) 2019-01-20
NZ627824A (en) 2016-02-26
CA2787691A1 (en) 2011-08-04
US11234985B2 (en) 2022-02-01
SI3494972T1 (sl) 2024-03-29
HK1179522A1 (en) 2013-10-04
EA202190473A2 (ru) 2021-06-30
CY1120457T1 (el) 2019-07-10
EP2531027A4 (en) 2013-07-03
EP3494972B1 (en) 2023-12-13
DK3494972T3 (da) 2024-01-29
MX2012008774A (es) 2012-08-17
DK3127542T3 (en) 2018-11-12
NZ627826A (en) 2016-01-29
IL221007A0 (en) 2012-09-24
CA3060290C (en) 2022-07-12
RS57728B1 (sr) 2018-12-31
DOP2012000205A (es) 2012-10-15
FR18C1043I2 (fr) 2019-10-11
US20180098992A1 (en) 2018-04-12
MX367937B (es) 2019-09-12
SI2932970T1 (en) 2018-07-31
PL3127542T3 (pl) 2019-03-29
CY1116509T1 (el) 2017-03-15
LT3127542T (lt) 2018-11-26
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
PH12018502489A1 (en) 2020-06-15
EA201290583A1 (ru) 2013-04-30
TN2012000376A1 (en) 2014-01-30
MX356891B (es) 2018-06-19
PH12016500195A1 (en) 2016-12-05

Similar Documents

Publication Publication Date Title
CO6602152A2 (es) En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga.
CY1125202T1 (el) Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο hiv
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EA201201509A1 (ru) Фармацевтические составы, содержащие пиоглитазон и линаглиптин
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
WO2016109217A3 (en) Btk inhibitors
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
CO6630124A2 (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
CL2017002229A1 (es) Inhibidores de bace1.
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses

Legal Events

Date Code Title Description
FG Application granted